Skip to main content
OpenTrials
Completed

NCT Number: NCT06087471

Snack Foods and Their Impact on Mental Health and the Gut-brain Axis

The aim of this study is to investigate the effects of snack foods on mental health and the gut-brain axis, in adults with mild to moderate symptoms of depression and anxiety.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Depression Anxiety Anxiety Disorders Behavior Behavioral Symptoms Mental Disorders Personal Satisfaction Psychological Well-Being

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Metabolic research unit, Franklin-Wilkins Building, 150 stamford street

London, SE19NH, United Kingdom

About this study

There is increasing evidence on the potential modulating role of healthy dietary patterns in managing symptoms of psychological distress including but not limited to depression and anxiety. Despite growing evidence, further research is required to investigate how dietary interventions may impact symptoms of depression and anxiety, as well as their mechanisms of action via the gut-brain axis. Consumption of snacks now contributes to roughly 17% and 21% of daily energy intake for men and women respectively. Therefore, snacks greatly impact nutritional intake and diet quality and can be a target of dietary manipulation for potential health benefits.

This will be the first randomised controlled trial to assess the impact of snack consumption on mental health in adults with mild to moderate symptoms of depression and anxiety. The trial will use a parallel design with a 12-week intervention. Stool and blood samples will be collected at the beginning and end of the intervention for measurement of the gut microbiota and biomarkers related to the gut-brain axis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18-45 years old.
  • Body mass index (BMI) between 18.50-29.99kg/m2
  • Score 10-29 on the patient health questionnaire anxiety and depression scale (PHQ-ADS) for mild to moderate symptoms of depression and anxiety.
  • Individuals who regularly consume snacks (Classified as ≥2 per day excluding fruit, vegetable, nut and seed snacks).
  • Willing to complete the 12-week intervention by adhering to snacks, complete mental health questionnaires, provide stool and blood samples, record weight and other anthropometric values and record food intake at various timepoints throughout the intervention.
  • Willing to adhere to the protocol and provide informed consent.
  • Fibre intake of <30g/d
  • Willing to discontinue use of pre and probiotics during the trial.

Exclusion criteria

  • Dislike of intervention products.
  • Allergy or intolerance to the intervention products
  • Self-report occurrence of substance dependency or severe mental health conditions (e.g., psychosis, schizophrenia, eating disorder). Those with depressive disorders or anxiety disorders will be included in the trial providing they meet all other inclusion criteria.
  • Regular consumption of experimental product as snacks and unwilling to complete a washout (no consumption for 4 weeks before baseline or during the study period).
  • Changes to medication for depression or anxiety within the last 3 months (e.g., dosage, frequency, type)
  • Initiation of any new medications for mental health or any form of talk therapy within the last 3 months.
  • Intention to start or alter medication or therapy for mental health during the study.
  • Current or previous antibiotic treatment within 4 weeks prior to the start of the study.
  • Consumption of probiotics or prebiotic products within the 2 weeks prior to the start of the study
  • Women who are pregnant, lactating or planning pregnancy
  • Unexplained or unintentional weight loss in the past six months
  • Medical history of any of the following: diabetes, major active or historic psychiatric conditions (e.g. schizophrenia), current eating disorder, alcohol abuse, active treatment for cancer in the last year, severe neurological, endocrine, renal, cardiac or pulmonary disease (or any other chronic medical condition), severe oesophagitis, gastritis or duodenitis, active diverticulitis or intestinal/colonic strictures, Coeliac disease, Crohn's disease or Ulcerative colitis, stem cell or organ transplant, gut resection surgery (excluding appendicectomy and cholecystectomy), bleeding disorder, anaphylaxis or any other major or chronic condition known to impact study outcome measures.

Treatment and study plan

Intervention snack

Dietary Supplement

The intervention snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).

Control Snack

Dietary Supplement

The control snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).

Primary outcomes

  1. Symptoms of depression and anxiety

    Time frame: Week 0 and 12

    Symptoms of depression and anxiety as measured by the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS). This is a 15-item self-report likert scale comprising the PHQ-8 and GAD-7. Scores can range from 0 to 48, cut points of 10,20 and 30 indicate mild, moderate and severe levels of depression/anxiety respectively.

Secondary outcomes

  1. Functional impairment

    Time frame: Weeks 0,6 and 12

    The self-report Work and social adjustment scale (WSAS) will be used to measure functional impairment scores. This is a self-report likert scale with 5 questions. Responses range from Not at all (0) to Very severely (8). 0-9, 10-19 and 20-40 represent low, moderate and severe impairment respectively.

  2. Sleep quality

    Time frame: Weeks 0,6 and 12

    The self-report Pittsburgh sleep quality index (PSQI) will be used to measure sleep quality. This is a 19-item questionnaire with seven subcategories; subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.

  3. Wellbeing

    Time frame: Weeks 0,6 and 12

    The self-report world health organisation five well-being index (WHO-5) will be used to measure wellbeing. The scale consists of 5 items rated from All of the time (5) to At no time (0).

  4. Quality of life

    Time frame: Weeks 0,6 and 12

    The self-report World Health Organisation Quality of Life Brief (WHOQOL-BREF) scale will be used to measure quality of life. This is a 26-item scale. Responses are rated on a 1-5 likert scale with 1 representing 'not at all' and 5 representing 'completely agree'. Scores are tabulated and multiplied by 4 to represent a score out of 100.

  5. Physical activity

    Time frame: Weeks 0,6 and 12

    The self-report international Physical Activity Questionnaire - Short form (IPAQ) will be used to measure physical activity.

  6. Symptoms of depression

    Time frame: Weeks 0,6 and 12

    The self-report Patient Health Questionnaire-8 (PHQ-8) will be used to measure symptoms of depression. The PHQ-8 is comprised of 8 items rated 0 to 3 with 0 representing 'not at all' and 3 representing 'nearly every day'.

  7. Symptoms of anxiety

    Time frame: Weeks 0,6 and 12

    The self-report Generalised Anxiety disorder-7 scale will be used to measure symptoms of anxiety. The GAD-7 is comprised of 7 questions rated 0 to 3 indicating not at all, to nearly every day respectively.

  8. Psychological Distress

    Time frame: Weeks 0,6 and 12

    The Kessler Psychological Distress Scale (K10) will be used to measure symptoms of psychological distress. The K10 is comprised of 10 questions rated on a 5-point likert scale. Scores range from 10-50.

  9. Faecal gut microbiota (composition, alpha- and beta-diversity)

    Time frame: Week 0 and 12

    Measured by 16S community profiling (Illumina Miseq) of bacterial genomic DNA isolated from stool samples.

  10. Faecal short-chain fatty acids (SCFA)

    Time frame: Week 0 and 12

    Measured by gas liquid chromatography of stool samples

  11. Faecal water

    Time frame: Week 0 and 12

    Determined from stool samples by oven-drying

  12. Gut symptoms

    Time frame: Week 0 and 12

    Measured using the Gastrointestinal Symptom Rating Scale (GSRS) (7-day diary; questionnaire)

  13. Stool frequency

    Time frame: Week 0 and 12

    Measured using self-reported number bowel movements daily recorded in a 7-day diary.

  14. Stool consistency

    Time frame: Week 0 and 12

    Measured using the Bristol stool form scale (7-day dairy; questionnaire)

  15. Serum Vitamin E levels

    Time frame: Week 0 and 12

    Measured in blood sample. Analysis of serum vitamin E levels by Liquid chromatography-mass spectrometry.

  16. Dietary intake

    Time frame: Week 0 and 12

    Measured using a 7-day food and drink diary

  17. Acceptability of snack products

    Time frame: Week 12

    Measured using an Acceptability of dietary intervention questionnaire developed by King's College London for use in dietary intervention studies. The questionnaire assesses acceptability using a number of domains including flavour, texture and portion size.

  18. Snack compliance

    Time frame: Week 12

    Measured via the return of unused snacks at the final visit (consumption of >75% of total snacks will be considered compliant).

  19. Adverse events

    Time frame: Week 0 to 12

    Interview-administered questionnaire

  20. Symptoms of depression and anxiety

    Time frame: Week 0,6 and 12

    Symptoms of depression and anxiety as measured by the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS). This is a 15-item self-report likert scale comprising the PHQ-8 and GAD-7. Scores can range from 0 to 48, cut points of 10,20 and 30 indicate mild, moderate and severe levels of depression/anxiety respectively.

  21. Change in symptoms of depression and anxiety

    Time frame: Week 0, 6 and 12

    Change symptoms of depression and anxiety as measured by the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS). This is a 15-item self-report likert scale comprising the PHQ-8 and GAD-7. Scores can range from 0 to 48, cut points of 10,20 and 30 indicate mild, moderate and severe levels of depression/anxiety respectively.

  22. Proportion of people with no, mild, moderate and severe symptoms of anxiety and depression

    Time frame: Week 0, 6 and 12

    Measured by the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS). This is a 15-item self-report likert scale comprising the PHQ-8 and GAD-7. Scores can range from 0 to 48, cut points of 10,20 and 30 indicate mild, moderate and severe levels of depression and anxiety respectively.

  23. Proportion of people with no, mild, moderate and severe symptoms of depression

    Time frame: Week 0, 6 and 12

    Measured by the PHQ-8 questionnaire. Scores can range from 0 to 24, cut points of 5, 10, 15 and 20 indicate mild, moderate, moderately severe and severe levels of depression, respectively.

  24. Proportion of people with no, mild, moderate and severe symptoms of anxiety

    Time frame: Week 0, 6 and 12

    Measured by the GAD-7. The GAD-7 is comprised of 7 questions rated 0 to 3 indicating not at all, to nearly every day respectively and scores range from 0-21. Cut points are 5, 10 and 15 indicating mild, moderate and severe levels of anxiety, respectively.

Sponsors and collaborators

Lead sponsor

King's College London

Other

Registry information

Official study title

Snack Foods and Their Impact on the Gut-Brain Axis: a Randomised Controlled Trial on Mental Health and the Gut Microbiota

Acronym: NutriMood

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Oct 17, 2023
Registry last updated
Feb 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.